• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

碳青霉烯类耐药鲍曼不动杆菌感染患者死亡的预测因素:系统评价和荟萃分析。

Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis.

机构信息

Department of Infectious Disease, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

出版信息

Am J Infect Control. 2019 Sep;47(9):1140-1145. doi: 10.1016/j.ajic.2019.03.003. Epub 2019 Apr 17.

DOI:10.1016/j.ajic.2019.03.003
PMID:31003750
Abstract

BACKGROUND

Carbapenem-resistant Acinetobacter baumannii (CRAB) tops the list of threats to human health. Studies exploring predictors of mortality in patients with CRAB infection produced conflicting results.

METHODS

A systematic search of the PubMed, Embase, and the Cochrane Library databases was performed from inception to June 2018 to identify studies reporting mortality predictors in patients infected with CRAB. Two authors independently assessed trials for inclusion and data extraction.

RESULTS

A total of 19 observational studies were enrolled in this study. Factors associated with mortality of patients infected with CRAB were inappropriate empirical antimicrobial treatment (odds ratio [OR], 5.04; 95% confidence interval [CI], 2.56-9.94), septic shock (OR, 5.65; 95% CI, 2.35-13.57), chronic liver disease (OR, 2.36; 95% CI, 1.33-4.16), chronic renal disease (OR, 2.02; 95% CI, 1.37-2.99), hypertension (OR, 1.74; 95% CI, 1.08-2.80), neutropenia (OR, 3.31; 95% CI, 1.25-8.77), immunosuppressant use (OR, 3.15; 95% CI, 1.94-5.11), total parenteral nutrition (OR, 1.66; 95% CI, 1.08-2.56), and intubation (OR, 5.03; 95% CI, 2.33-10.87). Acute Physiology and Chronic Health Evaluation II score at admission and Pitt bacteremia score at the onset of CRAB bacteremia were higher in nonsurvivors.

CONCLUSIONS

Our study suggests that severity of baseline condition and receiving inappropriate experience antibiotic therapy are major risk factors for higher mortality in patients with CRAB infections. These findings may help clinicians to take appropriate preventive measures and decrease mortality in such patients.

摘要

背景

耐碳青霉烯鲍曼不动杆菌(CRAB)位居威胁人类健康的威胁之首。探索 CRAB 感染患者死亡预测因素的研究结果存在矛盾。

方法

从建库到 2018 年 6 月,我们对 PubMed、Embase 和 Cochrane Library 数据库进行了系统检索,以确定报告 CRAB 感染患者死亡预测因素的研究。两位作者独立评估试验纳入和数据提取。

结果

共有 19 项观察性研究纳入本研究。与 CRAB 感染患者死亡相关的因素包括经验性抗菌治疗不当(比值比 [OR],5.04;95%置信区间 [CI],2.56-9.94)、感染性休克(OR,5.65;95%CI,2.35-13.57)、慢性肝病(OR,2.36;95%CI,1.33-4.16)、慢性肾病(OR,2.02;95%CI,1.37-2.99)、高血压(OR,1.74;95%CI,1.08-2.80)、中性粒细胞减少症(OR,3.31;95%CI,1.25-8.77)、免疫抑制剂使用(OR,3.15;95%CI,1.94-5.11)、全胃肠外营养(OR,1.66;95%CI,1.08-2.56)和插管(OR,5.03;95%CI,2.33-10.87)。入院时急性生理学和慢性健康评估 II 评分和 CRAB 菌血症发病时的 Pitt 菌血症评分在非幸存者中更高。

结论

本研究表明,基线状况的严重程度和接受不适当的经验性抗生素治疗是 CRAB 感染患者死亡率较高的主要危险因素。这些发现可能有助于临床医生采取适当的预防措施,降低此类患者的死亡率。

相似文献

1
Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis.碳青霉烯类耐药鲍曼不动杆菌感染患者死亡的预测因素:系统评价和荟萃分析。
Am J Infect Control. 2019 Sep;47(9):1140-1145. doi: 10.1016/j.ajic.2019.03.003. Epub 2019 Apr 17.
2
Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.碳青霉烯类耐药鲍曼不动杆菌菌血症患者的危险因素和临床结局。
J Microbiol Immunol Infect. 2012 Oct;45(5):356-62. doi: 10.1016/j.jmii.2011.12.009. Epub 2012 May 9.
3
A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia.一项病例对照研究,旨在确定碳青霉烯类耐药鲍曼不动杆菌菌血症 14 天死亡率的预测因素。
Clin Microbiol Infect. 2014 Dec;20(12):O1028-34. doi: 10.1111/1469-0691.12716. Epub 2014 Aug 11.
4
Changes in the early mortality of adult patients with carbapenem-resistant Acinetobacter baumannii bacteremia during 11 years at an academic medical center.一所学术医疗中心11年间耐碳青霉烯鲍曼不动杆菌菌血症成年患者早期死亡率的变化
J Infect Chemother. 2019 Jan;25(1):6-11. doi: 10.1016/j.jiac.2018.09.011. Epub 2018 Oct 19.
5
Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.希腊重症监护病房耐碳青霉烯类 versus 碳青霉烯类敏感鲍曼不动杆菌菌血症:危险因素、临床特征和结局。
Infection. 2010 Jun;38(3):173-80. doi: 10.1007/s15010-010-0008-1. Epub 2010 Mar 12.
6
Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.医院获得性耐碳青霉烯鲍曼不动杆菌肺炎患者的危险因素和死亡率。
Am J Infect Control. 2013 Jul;41(7):e59-63. doi: 10.1016/j.ajic.2013.01.006. Epub 2013 Mar 21.
7
Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.碳青霉烯类耐药和接受积极抗菌治疗对鲍曼不动杆菌血流感染临床结局的影响。
Antimicrob Agents Chemother. 2011 Oct;55(10):4844-9. doi: 10.1128/AAC.01728-10. Epub 2011 Aug 8.
8
Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy.碳青霉烯类耐药鲍曼不动杆菌菌血症患者死亡的危险因素:适当抗菌治疗的影响。
J Korean Med Sci. 2012 May;27(5):471-5. doi: 10.3346/jkms.2012.27.5.471. Epub 2012 Apr 25.
9
Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections.碳青霉烯类耐药鲍曼不动杆菌血流感染的临床和微生物学特征。
J Med Microbiol. 2011 May;60(Pt 5):605-611. doi: 10.1099/jmm.0.029439-0. Epub 2011 Jan 13.
10
Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.碳青霉烯类耐药鲍曼不动杆菌菌血症患者死亡的危险因素。
J Microbiol Immunol Infect. 2016 Dec;49(6):934-940. doi: 10.1016/j.jmii.2014.10.006. Epub 2014 Nov 11.

引用本文的文献

1
The global epidemiology of carbapenem-resistant .耐碳青霉烯类药物的全球流行病学情况
JAC Antimicrob Resist. 2025 Jul 29;7(4):dlaf134. doi: 10.1093/jacamr/dlaf134. eCollection 2025 Aug.
2
Evaluation of Infections Caused by Carbapenem-Resistant , , and in an Intensive Care Unit: A Retrospective Study.重症监护病房中耐碳青霉烯类[细菌名称缺失]和[细菌名称缺失]引起的感染评估:一项回顾性研究
Antibiotics (Basel). 2025 Jul 12;14(7):700. doi: 10.3390/antibiotics14070700.
3
Efficacy of cefoperazone-sulbactam as a component of combination therapy for carbapenem-resistant Acinetobacter baumannii bloodstream infection in intensive care units: a multicenter retrospective propensity score-matched study.
头孢哌酮-舒巴坦作为重症监护病房耐碳青霉烯鲍曼不动杆菌血流感染联合治疗方案组成部分的疗效:一项多中心回顾性倾向评分匹配研究
BMC Infect Dis. 2025 Jul 1;25(1):872. doi: 10.1186/s12879-025-11205-w.
4
Risk and Prognostic Factors for Bloodstream Infections Due to Clonally Transmitted ST2 with OXA-23, and OXA-66: A Retrospective Study.克隆传播的携带OXA-23和OXA-66的ST2所致血流感染的风险及预后因素:一项回顾性研究
Infect Drug Resist. 2025 Apr 14;18:1867-1879. doi: 10.2147/IDR.S498212. eCollection 2025.
5
Multidrug-Resistant : Risk Factors for Mortality in a Tertiary Care Teaching Hospital.多重耐药:三级护理教学医院中死亡率的风险因素
Trop Med Infect Dis. 2025 Jan 6;10(1):15. doi: 10.3390/tropicalmed10010015.
6
Can risk factors and risk scores help predict colonization and infection in multidrug-resistant gram-negative bacteria?风险因素和风险评分能否帮助预测多重耐药革兰氏阴性菌的定植和感染?
Antimicrob Steward Healthc Epidemiol. 2024 Nov 11;4(1):e196. doi: 10.1017/ash.2024.455. eCollection 2024.
7
Optimizing Treatment Strategies for Carbapenem-Resistant Acinetobacter Baumannii-Associated Pneumonia: A Multicenter Study in Chinese Hospitals.优化耐碳青霉烯鲍曼不动杆菌相关性肺炎的治疗策略:一项在中国医院开展的多中心研究
Infect Drug Resist. 2024 Oct 13;17:4403-4415. doi: 10.2147/IDR.S473088. eCollection 2024.
8
Biofilm Formation, Antibiotic Resistance, and Infection (BARI): The Triangle of Death.生物膜形成、抗生素耐药性与感染(BARI):死亡三角
J Clin Med. 2024 Sep 27;13(19):5779. doi: 10.3390/jcm13195779.
9
Analysis of risk factors and different treatments for infections caused by carbapenem-resistant Acinetobacter baumannii in Shaanxi, China.中国陕西耐碳青霉烯类鲍曼不动杆菌感染的危险因素及不同治疗方法分析。
BMC Infect Dis. 2024 Oct 9;24(1):1130. doi: 10.1186/s12879-024-10036-5.
10
An overview of sulbactam-durlobactam approval and implications in advancing therapeutics for hospital-acquired and ventilator-associated pneumonia by complex: A narrative review.舒巴坦-度洛巴坦获批情况概述及其对推进医院获得性肺炎和呼吸机相关性肺炎治疗方案的影响:一项叙述性综述。
Health Sci Rep. 2024 Sep 9;7(9):e70066. doi: 10.1002/hsr2.70066. eCollection 2024 Sep.